Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

Bastian von TresckowDepartment of Internal Medicine I, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Kerpener Str. 62, Cologne, Germany; Correspondence[email protected]

Franck MorschhauserHematology Department, CHRU Lille Hopital Claude Huriez, Lille, France;

Jeffrey SzerBone Marrow Transplant Unit, Royal Melbourne Hospital, Parkville, VIC, Australia;

Dennis A. EichenauerDepartment of Internal Medicine I, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Kerpener Str. 62, Cologne, Germany;

Jeremy S. AbramsonMassachusetts General Hospital, Yawkey Center, Suite 9A, Boston, MA, USA;

Anna SuredaHematology Department, Hospital De La Santa Creu I Sant Pau, Mas Casanovas, Barcelona, Spain; ;Hematology Department, Institut Català D’Oncologia – L’Hospitalet, Gran via, Barcelona, Spain

Andreas EngertDepartment of Internal Medicine I, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Kerpener Str. 62, Cologne, Germany;

show all

References

Rancea M, von Tresckow B, Monsef I, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. Crit Rev Oncol Hematol. 2014;92:1–10.
PubMed Web of Science ®Google Scholar
Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24:2430–2434.
PubMed Web of Science ®Google Scholar
von Tresckow B, Muller H, Eichenauer DA, et al. Outcome and risk factors of Hodgkin lymphoma patients who relapse or progress after autologous stem cell transplant. Leuk Lymphoma. 2014;55:1922–1924.
PubMed Web of Science ®Google Scholar
Arai S, Fanale M, Devos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531–2533.
PubMed Web of Science ®Google Scholar
Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28:5074–5080.
PubMed Web of Science ®Google Scholar
Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;9:1853–1862.
Web of Science ®Google Scholar
Sweetenham J, Walewski J, Nademanee AP, et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Blood. 2015;126:3172–3172.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date